Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T14:15:51.356Z.
Calculation as of: 2026-10-06T14:15:51.356Z.
Quote observation: 2026-10-06T14:15:23.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 29544bddba9647c45f1d116a926e76fce0232fba061b4e126f75ac7ab8440d73
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$847.33M
EV/EBIT Ratio
N/A
TTM Avg
76.83x
3Y Avg
76.83x
5Y Avg
76.83x
Market Cap
$868.65M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$878.06M
EV/EBIT Ratio
5.86x
TTM Avg
5.93x
3Y Avg
5.93x
5Y Avg
5.93x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Beta Bionics, Inc. (BBNX) | $844.91M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $847.33M | N/A | 76.83x | 76.83x | 76.83x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $868.65M | N/A | N/A | N/A | N/A |
| Alumis Inc. (ALMS)vs › | $826.99M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $878.06M | 5.86x | 5.93x | 5.93x | 5.93x |
| Apnimed, Inc. (APMD)vs › | $817.57M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $818.57M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $809.02M | N/A | 9.35x | 9.35x | 9.35x |
| InMode Ltd. (INMD)vs › | $809.04M | 6.03x | 7.17x | 8.31x | 13.83x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $808.29M | N/A | 103.45x | 72.64x | 72.64x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
